# Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)

> **NCT01463683** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 722 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** 2XP HEPTAVAX™-II SC
- **BIOLOGICAL:** 1XP HEPTAVAX™-II SC
- **BIOLOGICAL:** 2XP HEPTAVAX™-II IM

## Key facts

- **NCT ID:** NCT01463683
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-29
- **Primary completion:** 2012-11-06
- **Final completion:** 2012-11-06
- **Target enrollment:** 722 (ACTUAL)
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01463683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01463683, "Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01463683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*